Vitamin D therapy in canine atopic dermatitis

2018 ◽  
Vol 182 (14) ◽  
pp. 403-405 ◽  
Author(s):  
Tina Kotnik
Keyword(s):  
Vitamin D ◽  
Atopic Dermatitis ◽  
Canine Atopic Dermatitis

Vitamin D shows in vivo efficacy in a placebo-controlled, double-blinded, randomised clinical trial on canine atopic dermatitis

2018 ◽  
Vol 182 (14) ◽  
pp. 406-406 ◽  
Author(s):  
Christoph J Klinger ◽  
Stefan Hobi ◽  
Cornelia Johansen ◽  
Hans-Joachim Koch ◽  
Karin Weber ◽  
...  
Keyword(s):  
Vitamin D ◽  
Atopic Dermatitis ◽  
Water Loss ◽  
Clinical Signs ◽  
Group Versus ◽  
Clinical Effects ◽  
Vitamin D Metabolites ◽  
Canine Atopic Dermatitis ◽  
Skin Ph ◽  
Double Blinded

Atopic dermatitis (AD) in dogs is among the most common skin diseases in small animal practice. It is an inflammatory disease based on a genetic predisposition to develop hypersensitivity against environmental and food allergens and typical clinical signs up exposure. Treatment sometimes can be difficult and associated with adverse effects. Previous studies evaluating cholecalciferol as treatment for human AD have shown promising results. With canine AD being a good animal model for its human counterpart, it was hypothesised that cholecalciferol might have beneficial clinical effects in dogs, too. In this randomised, placebo-controlled, double-blinded eight-week cross-over study, 23 client-owned dogs received either systemic cholecalciferol (n=16), a vitamin D receptor analogue (n=8) or placebo (n=13). Blood samples for ionised calcium were obtained regularly during the study, and Canine Atopic Dermatitis Extent and Severity Index and pruritus scores, blood levels of vitamin D metabolites, measurements of skin pH and transepidermal water loss were determined before and after. Pruritus and lesion scores decreased significantly in the cholecalciferol group versus placebo. No differences in water loss or skin pH were observed. An increase in serum 25-hydroxycholecalciferol strongly correlated with a reduction in pruritus. Systemic cholecalciferol may be a viable treatment option for canine AD.

scholarly journals IgE reactivity to Pacific cod (Gadus macrocephalus) fish allergens in dogs with canine atopic dermatitis

2019 ◽  
Vol 143 (2) ◽  
pp. AB67
Author(s):  
Ichiro Imanishi ◽  
Jumpei Uchiyama ◽  
Takako Matsuda ◽  
Keijiro Mizukami ◽  
Hidekatsu Shimakura ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Pacific Cod ◽  
Canine Atopic Dermatitis ◽  
Ige Reactivity ◽  
Pacific Cod Gadus Macrocephalus ◽  
Gadus Macrocephalus

Dose–response association between vitamin D deficiency and atopic dermatitis in children, and effect modification by gender: a case-control study

2019 ◽  
pp. 1-6
Author(s):  
Amal Ahmed Mohamed ◽  
Eman Mohamed Salah Ahmed ◽  
Youssef M. K. Farag ◽  
Nermeen Ibrahim Bedair ◽  
Nourelhuda Ahmed Nassar ◽  
...  
Keyword(s):  
Vitamin D ◽  
Atopic Dermatitis ◽  
Vitamin D Deficiency ◽  
Dose Response ◽  
Case Control Study ◽  
Case Control ◽  
Effect Modification ◽  
Control Study

Evaluation of the cutaneous expression of IL-17, IL-22, IL-31, and their receptors in canine atopic dermatitis

2021 ◽  
Vol 136 ◽  
pp. 74-80
Author(s):  
Sayaka Shiomitsu ◽  
James Gillen ◽  
Salvatore Frasca ◽  
Domenico Santoro
Keyword(s):  
Atopic Dermatitis ◽  
Canine Atopic Dermatitis

Expression of thymic stromal lymphopoietin in canine atopic dermatitis

2013 ◽  
Vol 24 (1) ◽  
pp. 54-e14 ◽  
Author(s):  
Jolanta Klukowska-Rötzler ◽  
Ludovic Chervet ◽  
Eliane J. Müller ◽  
Petra Roosje ◽  
Eliane Marti ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Thymic Stromal Lymphopoietin ◽  
Canine Atopic Dermatitis

Preliminary evaluation of cytosine-phosphate-guanine oligodeoxynucleotides bound to gelatine nanoparticles as immunotherapy for canine atopic dermatitis

2017 ◽  
Vol 181 (5) ◽  
pp. 118-118 ◽  
Author(s):  
I. Wagner ◽  
K. J. Geh ◽  
M. Hubert ◽  
G. Winter ◽  
K. Weber ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Mrna Expression ◽  
Transforming Growth Factor ◽  
Transforming Growth Factor Β ◽  
Interferon Γ ◽  
Preliminary Evaluation ◽  
Cpg Odn ◽  
Canine Atopic Dermatitis ◽  
Group 2 ◽  
Group 1

Cytosine-phosphate-guanine oligodeoxynucleotides (CpG ODN) are a promising new immunotherapeutic treatment option for canine atopic dermatitis (AD). The aim of this uncontrolled pilot study was to evaluate clinical and immunological effects of gelatine nanoparticle (GNP)-bound CpG ODN (CpG GNP) on atopic dogs. Eighteen dogs with AD were treated for 8 weeks (group 1, n=8) or 18 weeks (group 2, n=10). Before inclusion and after 2 weeks, 4 weeks, 6 weeks (group 1+2), 8 weeks, 12 weeks and 16 weeks (group 2) 75 µg CpG ODN/dog (bound to 1.5 mg GNP) were injected subcutaneously. Pruritus was evaluated daily by the owner. Lesions were evaluated and serum concentrations and mRNA expressions of interferon-γ, tumour necrosis factor-α, transforming growth factor-β, interleukin (IL) 10 and IL-4 (only mRNA expression) were determined at inclusion and after 8 weeks (group 1+2) and 18 weeks (group 2). Lesions and pruritus improved significantly from baseline to week 8. Mean improvements from baseline to week 18 were 23 per cent and 44 per cent for lesions and pruritus, respectively, an improvement of ≥50 per cent was seen in six out of nine and three out of six dogs, respectively. IL-4 mRNA expression decreased significantly. The results of this study show a clinical improvement of canine AD with CpG GNP comparable to allergen immunotherapy. Controlled studies are needed to confirm these findings.

Sign in / Sign up

Export Citation Format

Share Document